WO2007016590A3 - Ovr232v3 antibody compositions and methods of use - Google Patents

Ovr232v3 antibody compositions and methods of use Download PDF

Info

Publication number
WO2007016590A3
WO2007016590A3 PCT/US2006/029995 US2006029995W WO2007016590A3 WO 2007016590 A3 WO2007016590 A3 WO 2007016590A3 US 2006029995 W US2006029995 W US 2006029995W WO 2007016590 A3 WO2007016590 A3 WO 2007016590A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovr232v3
antibody
antibodies
nucleic acid
mammal
Prior art date
Application number
PCT/US2006/029995
Other languages
French (fr)
Other versions
WO2007016590A2 (en
Inventor
Shu-Hui Liu
Jackie Papkoff
Original Assignee
Diadexus Inc
Shu-Hui Liu
Jackie Papkoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc, Shu-Hui Liu, Jackie Papkoff filed Critical Diadexus Inc
Publication of WO2007016590A2 publication Critical patent/WO2007016590A2/en
Publication of WO2007016590A3 publication Critical patent/WO2007016590A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

The invention provides isolated anti-ovarian, colon, prostate, or lung cancer antigen (Ovr232v3) antibodies that bind to Ovr232v3 on a mammalian cell. The invention also encompasses compositions containing an anti-Ovr232v3 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr232v3 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr232v3 antibodies. The invention encompasses a method of producing the anti-Ovr232v3 antibodies. Other aspects of the invention are a method of killing an Ovr232v3-expressing cancer cell via contacting the cancer cell with an anti-Ovr232v3 antibody and a method of alleviating or treating an Ovr232v3 -expressing cancer in a mammal via administering a therapeutically effective amount of the anti-Ovr232v3 antibody to the mammal.
PCT/US2006/029995 2005-07-29 2006-07-31 Ovr232v3 antibody compositions and methods of use WO2007016590A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70550205P 2005-07-29 2005-07-29
US60/705,502 2005-07-29

Publications (2)

Publication Number Publication Date
WO2007016590A2 WO2007016590A2 (en) 2007-02-08
WO2007016590A3 true WO2007016590A3 (en) 2007-11-22

Family

ID=37709328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029995 WO2007016590A2 (en) 2005-07-29 2006-07-31 Ovr232v3 antibody compositions and methods of use

Country Status (1)

Country Link
WO (1) WO2007016590A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227000B2 (en) 2006-09-28 2016-01-05 Smith & Nephew, Inc. Portable wound therapy system
USD806256S1 (en) 2012-05-23 2017-12-26 Smith & Nephew Plc Medical dressing

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298453B2 (en) 2003-10-28 2022-04-12 Smith & Nephew Plc Apparatus and method for wound cleansing with actives
GB0508531D0 (en) 2005-04-27 2005-06-01 Smith & Nephew Sai with ultrasound
GB0723872D0 (en) 2007-12-06 2008-01-16 Smith & Nephew Apparatus for topical negative pressure therapy
US9033942B2 (en) 2008-03-07 2015-05-19 Smith & Nephew, Inc. Wound dressing port and associated wound dressing
US8021347B2 (en) 2008-07-21 2011-09-20 Tyco Healthcare Group Lp Thin film wound dressing
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US8162907B2 (en) 2009-01-20 2012-04-24 Tyco Healthcare Group Lp Method and apparatus for bridging from a dressing in negative pressure wound therapy
US20100324516A1 (en) 2009-06-18 2010-12-23 Tyco Healthcare Group Lp Apparatus for Vacuum Bridging and/or Exudate Collection
MX2013007304A (en) 2010-12-22 2013-07-29 Smith & Nephew Inc Apparatuses and methods for negative pressure wound therapy.
WO2014020440A1 (en) 2012-08-01 2014-02-06 Smith & Nephew Plc Wound dressing
EP3406231B1 (en) 2012-08-01 2022-04-13 Smith & Nephew plc Wound dressing and method of treatment
EP2994176B1 (en) 2013-05-10 2020-07-08 Smith & Nephew plc Fluidic connector for irrigation and aspiration of wounds
US10076594B2 (en) 2015-05-18 2018-09-18 Smith & Nephew Plc Fluidic connector for negative pressure wound therapy
GB201718014D0 (en) 2017-11-01 2017-12-13 Smith & Nephew Dressing for negative pressure wound therapy with filter
GB201811449D0 (en) 2018-07-12 2018-08-29 Smith & Nephew Apparatuses and methods for negative pressure wound therapy
IT202000031838A1 (en) * 2020-12-22 2022-06-22 Saverio Alberti PLATFORM FOR OBTAINING MONOCLONAL ANTIBODIES DIRECTED AGAINST TUMOR-SPECIFIC PROCESSED ANTIGENS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053079A2 (en) * 2002-12-06 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053079A2 (en) * 2002-12-06 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORCHARDT P.E. ET AL.: "Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer", CANCER RES., vol. 63, 15 August 2003 (2003-08-15), pages 5084 - 5090, XP002458367 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227000B2 (en) 2006-09-28 2016-01-05 Smith & Nephew, Inc. Portable wound therapy system
USD806256S1 (en) 2012-05-23 2017-12-26 Smith & Nephew Plc Medical dressing
USD806242S1 (en) 2012-05-23 2017-12-26 Smith & Nephew Plc Flexible port used to connect a wound dressing to a source of negative pressure
USD806243S1 (en) 2012-05-23 2017-12-26 Smith & Nephew Plc Flexible port used to connect a wound dressing to a source of negative pressure
USD820990S1 (en) 2012-05-23 2018-06-19 Smith & Nephew Plc Medical dressing
US11590029B2 (en) 2012-05-23 2023-02-28 Smith & Nephew Plc Apparatuses and methods for negative pressure wound therapy

Also Published As

Publication number Publication date
WO2007016590A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007016590A3 (en) Ovr232v3 antibody compositions and methods of use
WO2004101756A3 (en) Ovr110 antibody compositions and methods of use
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
WO2006074418A3 (en) Ovr110 antibody compositions and methods of use
WO2006053110A3 (en) Ovr110 antibody compositions and methods of use
IL149116A0 (en) Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2007002223A3 (en) Cd19 antibodies and their uses
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2006076691A3 (en) Irta-2 antibodies and their uses
SG170080A1 (en) Human monoclonal antibodies to o8e
MX2010008570A (en) Alpha 5 - beta 1 antibodies and their uses.
MX2009003306A (en) Human antibodies that bind cxcr4 and uses thereof.
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2008067283A3 (en) Ovr110 antibody compositions and methods of use
EA200800229A1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LIGAND-1 PROGRAMMED CELL DECLINATION (PD-L1)
WO2008076560A3 (en) Human monoclonal antibodies to btla and methods of use
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
WO2007038637A3 (en) Human monoclonal antibodies to cd70
EA200801509A1 (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MX2010005830A (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use.
IN2009KN02404A (en)
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2004104173A3 (en) Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06800636

Country of ref document: EP

Kind code of ref document: A2